The rates of immune-mediated adverse effects, such as hepatitis, rashes, hyperthyroidism and hypothyroidism, were higher in PD-1/PD-L1 inhibitor monotherapy compared to chemotherapy across all three studies. Here, CD274 is linked to hypothyroidism.